31 October 2022 : Clinical Research
hOGG1 rs1052133 Polymorphism and Prostate Cancer Risk: A Chinese Case-Control Study and Meta-Analysis
Hanjiang Xu123BCDEF*, Meng Zhang123BCDEF, Zongyao Hao123AC, Chaozhao Liang123ADOI: 10.12659/MSM.938012
Med Sci Monit 2022; 28:e938012
Table 1 Comparison of clinical pathological characteristics between prostate cancer cases and controls.
| Characteristics | Controls | Cases | P-value* |
|---|---|---|---|
| Number | 243 | 160 | |
| Age, (years±SD) | 71.30±8.80 | 70.09±7.14 | 0.148 |
| PSA level (n) | |||
4| / | 46 (28.75) | | |
| 10≤n≤20 ng/ml | / | 50 (31.25) | |
| >20 ng/ml | / | 64 (40.00) | |
| Gleason score (n) | |||
| 6 | / | 29 | |
| 7 | 70 | ||
| 8 | 30 | ||
| 9 | 26 | ||
| 10 | / | 5 | |
| TNM stage (n) | |||
| T1N0M0 | 5 | ||
| T2N0M0 | 104 | ||
| T2N0M1 | 4 | ||
| T2N1M0 | 7 | ||
| T2N1M1 | 1 | ||
| T3N0M0 | 15 | ||
| T3N0M1 | 3 | ||
| T3N1M0 | 9 | ||
| T3N1M1 | 4 | ||
| T3NxM0 | 1 | ||
| T3NxM1 | 1 | ||
| T4N1M0 | 1 | ||
| T4N0M1 | 1 | ||
| T4N1M1 | 5 | ||
| T4NxM1 | 1 | ||
| * t-test. PSA – prostatic specific antigen; SD – standard deviation; n – number; TNM – Tumor, Nodes, Metastases. | |||